Biotech

All Articles

AstraZeneca posts records on in-house competitors to AbbVie, Pfizer ADCs

.AstraZeneca has discussed an early examine the efficiency of its own in-house antibody-drug conjuga...

iTeos- GSK's TIGIT celebrity reveals relevant enhancement

.After declaring a phase 3 launch based upon good midstage end results, iTeos and GSK are actually e...

More collective FDA can accelerate uncommon ailment R&ampD: report

.The FDA should be actually more available and also joint to let loose a rise in commendations of un...

Zenas, MBX, Bicara scalp to Nasdaq in hot time for biotech IPOs

.It's an unusually busy Friday for biotech IPOs, with Zenas BioPharma, MBX and Bicara Therapeutics a...

Atea's COVID antiviral fails to halt hospital stays in phase 3

.Atea Pharmaceuticals' antiviral has fallen short an additional COVID-19 test, yet the biotech still...

Neurocrine's bid to conserve schizophrenia prospect stops working

.Neurocrine Biosciences' schizophrenia system pivot has actually failed. The biotech was actually un...

Sanofi spends $110M upfront for late-stage radioligand therapy

.Sanofi has made an overdue access to the radioligand party, paying 100 thousand euros ($ 110 thousa...

F 2G brings up $100M for second effort to receive brand-new antifungal to market

.After F2G's initial attempt to obtain a brand-new lesson of antifungal to market was actually hinde...

Moderna targets $1.1 B in R&ampD spending slices, drops 5 plans in the middle of profits tensions

.Moderna has actually vowed to reduce R&ampD spending by $1.1 billion through 2027. The choice to sh...

Sanofi's $80M bank on Key dystrophy medication ends in stage 3 go belly up

.Simply 4 months after Sanofi bet $80 million in beforehand cash on Pivot Therapies' losmapimod, the...